GT200300286A - Derivados biciclicos para el tratamiento del crecimiento celular anormal - Google Patents

Derivados biciclicos para el tratamiento del crecimiento celular anormal

Info

Publication number
GT200300286A
GT200300286A GT200300286A GT200300286A GT200300286A GT 200300286 A GT200300286 A GT 200300286A GT 200300286 A GT200300286 A GT 200300286A GT 200300286 A GT200300286 A GT 200300286A GT 200300286 A GT200300286 A GT 200300286A
Authority
GT
Guatemala
Prior art keywords
treatment
cellular growth
abnormal cellular
bicycle derivatives
bicycle
Prior art date
Application number
GT200300286A
Other languages
English (en)
Inventor
John Charles Kath
Zhengyu Liu
Maria Steflik Brown
Susan Jane Truesdell
Ruby Anthea Szewc
Steven Mark Winter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of GT200300286A publication Critical patent/GT200300286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL COMPUESTO DE FORMULA GENERAL I EN LA QUE R1,R2,R3,R5, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON DE UTILIDAD EN EL TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL POR LO QUE VA A INFLUIR CONTRA LOS TRASTORNOS PROLIFERATIVOS TALES COMO EL CANCER.
GT200300286A 2002-12-18 2003-12-16 Derivados biciclicos para el tratamiento del crecimiento celular anormal GT200300286A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43448602P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
GT200300286A true GT200300286A (es) 2004-08-13

Family

ID=32595280

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300286A GT200300286A (es) 2002-12-18 2003-12-16 Derivados biciclicos para el tratamiento del crecimiento celular anormal

Country Status (20)

Country Link
US (1) US20040254204A1 (es)
EP (1) EP1575592A1 (es)
JP (1) JP2006513179A (es)
KR (1) KR20050085749A (es)
CN (1) CN1729001A (es)
AR (1) AR042480A1 (es)
AU (1) AU2003303045A1 (es)
BR (1) BR0317433A (es)
CA (1) CA2510323A1 (es)
GT (1) GT200300286A (es)
MX (1) MXPA05006335A (es)
NL (1) NL1025044C2 (es)
NO (1) NO20053483L (es)
PA (1) PA8592801A1 (es)
PE (1) PE20040905A1 (es)
PL (1) PL377686A1 (es)
RU (1) RU2005119172A (es)
TW (1) TW200424190A (es)
WO (1) WO2004054585A1 (es)
ZA (1) ZA200504147B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
MXPA06001989A (es) * 2003-08-18 2006-05-17 Pfizer Prod Inc Programa de dosificacion para un nuevo agente anticanceroso.
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
JP2008542356A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 異常な細胞増殖の治療用の二環式誘導体
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711783A1 (en) * 1994-11-08 1996-05-15 Glaxo, S.A. Antifungal Sordarin derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
CN1391562A (zh) * 1999-09-21 2003-01-15 阿斯特拉曾尼卡有限公司 用作药物的喹唑啉衍生物
BR0017067A (pt) * 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
DE60223279T2 (de) * 2001-11-30 2008-05-29 Osi Pharmaceuticals, Inc. Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
BR0214499A (pt) * 2001-12-12 2005-05-10 Pfizer Prod Inc Derivados de quinazolina para o tratamento do crescimento anormal das células
JP4202926B2 (ja) * 2001-12-12 2008-12-24 ファイザー・プロダクツ・インク Ｅ−２−メトキシ−ｎ−（３−（４−（３−メチル−ピリジン−３−イロキシ）−フェニルアミノ）−キナゾリン−６−イル）−アリル）−アセトアミドの塩形態、その製造および癌に対するその使用

Also Published As

Publication number Publication date
NO20053483L (no) 2005-09-19
AU2003303045A1 (en) 2004-07-09
US20040254204A1 (en) 2004-12-16
WO2004054585A1 (en) 2004-07-01
JP2006513179A (ja) 2006-04-20
PA8592801A1 (es) 2004-07-26
NL1025044C2 (nl) 2005-02-15
AR042480A1 (es) 2005-06-22
NO20053483D0 (no) 2005-07-18
CN1729001A (zh) 2006-02-01
ZA200504147B (en) 2006-07-26
NL1025044A1 (nl) 2004-06-21
KR20050085749A (ko) 2005-08-29
EP1575592A1 (en) 2005-09-21
TW200424190A (en) 2004-11-16
MXPA05006335A (es) 2005-08-26
PL377686A1 (pl) 2006-02-06
BR0317433A (pt) 2005-11-16
CA2510323A1 (en) 2004-07-01
PE20040905A1 (es) 2005-01-18
RU2005119172A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
GT200300296A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
GT200500242A (es) Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
GT200500103A (es) 4-fenilamino-quinazolin-6-il-amidas
GT200600024A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
ECSP066447A (es) Derivados de isoquinolina 1,4-disustituida como inhibidores raf-quinasa útiles para el tratamiento de enfermedades proliferativas
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
GT200300177A (es) Terapia de combinacion para enfermedades hiperproliferativas
GT200300286A (es) Derivados biciclicos para el tratamiento del crecimiento celular anormal
GT200300289A (es) Derivados de pirrolopirimidina
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
GT200500157A (es) Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa
GT200600217A (es) Proceso para la sintesis de compuestos organicos
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
ECSP11010880A (es) Compuestos orgánicos
BRPI0518169A (pt) tiazolil-dihidro-indazóis
GT200400274A (es) Nuevos derivados de quinolina
UY29668A1 (es) Nuevos derivados de heptaazafenaleno, procedimientos para su obtencinn, ase como utilizacinn de estos como agentes protectores contra la radicacinn uv.-
ECSP11010804A (es) Compuestos orgánicos
GT200600167A (es) Derivados de dihidrobenzofurano y usos de los mismos
DE602006010433D1 (de) Für die behandlung von obesitas geeignete tricyclische amidderivate
ECSP11010816A (es) Nuevos Compuestos
GT200500317A (es) Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
GT200600326A (es) Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas
GT200600178A (es) Derivados de aminoacidos